Model Estimated Increased Cure Rate Associated With Adjuvant Nivolumab for Muscle-Invasive Urothelial Carcinoma
PHILADELPHIA (January 26, 2024) — Patients with muscle-invasive urothelial carcinoma who underwent surgery to remove their tumor appeared to have an overall survival benefit from subsequent systemic therapy with the immune checkpoint inhibitor nivolumab, according to an analysis by researchers at Fox Chase Cancer Center.